progestin and adipoQ receptor family member 4Genealiases: []
Q-omics provides the consensus-scored PAQR4 profile across patient tissues and cancer cell-line models. PAQR4 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, PAQR4 is differentially expressed in 17, with the highest sampling consensus in COAD. Additionally, PAQR4 RNA expression shows 17,499 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight MESO, COAD, and TGCT as cancer lineages where PAQR4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PAQR4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PAQR4 survival associations across molecular data types. PAQR4 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (3) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PAQR4 RNA expression–survival associations across cancer types. High PAQR4 expression shows unfavorable associations in MESO, KIRP, BLCA, KICH and KIRC, but favorable associations in STAD. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for PAQR4 RNA expression.
This table summarizes PAQR4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 17, while mass-spec protein shows differences in 3. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for PAQR4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PAQR4 shows higher tumor expression in COAD, HNSC, KIRC, KIRP, BLCA and THCA. The COAD box plot shows higher PAQR4 RNA expression in tumor versus normal tissue (log2 FC = +2.825, t-test p < 0.001).
This table shows molecular features associated with PAQR4 in patient tissues and cancer cell lines. In patient samples, PAQR4 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, PAQR4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and BLOOD_Leukemia.
